Our Company

EWHA DrugDesignHouse (EDDH), based in Seoul, Republic of Korea, was founded in 2015 and is committed to developing anti-fibrotic agents for various indications and a longevity medicine.

Our main pipeline, Vactosertib is a highly potent, selective, and orally bioavailable small-molecule TGF-β type I receptor kinase (ALK5) inhibitor, which is expected to work as an effective anti-fibrotic agent that society desperately needs.

Led by our scientific founder, who has developed a number of novel drugs including Vactosertib, we are now developing other small-molecule anti-fibrotic agents for various indications and a longevity medicine.

History

2022 06 Applied for a US patent of intestine-specific, partial FXR agonist (US63/356261)

2021 08 Applied for a US patent of EW-7197 (Vactosertib) for use of ophthalmic indication (US20230047393 A1; WO2023013993 A1)

2021 04 Out-licensed the right of EW-7197 (Vactosertib) for use of IBD to Biophammer, Inc.

2015 05 In-licensed the right of EW-7197 (Vactosertib) from Ewha Womans University for use of all indications except oncology

2015 03 Established EWHA DrugDesignHouse, Co., Ltd. at Ewha Womans University